companydata.dkcompanydata.dk

BILLEV PHARMA ApS: Financial statements 2024

CVR: 81814813

Source: annual report 2024, Danish Business Authority

01/05/202330/04/2024

BILLEV PHARMA ApS (CVR 81814813) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK 24,763,226 and a net result of DKK 3,378,539 compared with DKK 4,943,056 the year before. That is a decrease of 14.8% compared with the year before. Equity in the 2024 report amounted to DKK 3,698,539. The solvency ratio was 53.5%. The company had 19 employees in the financial year.

Gross Profit
DKK 24,763,226
Profit/Loss
DKK 3,378,539
Equity
DKK 3,698,539
Total Assets
DKK 6,910,953
Employees
19

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2024-24.8 mio.3.4 mio.3.7 mio.19
2023-29.1 mio.4.9 mio.5.3 mio.21
2022-30.2 mio.6 mio.6.3 mio.21
2021-25.6 mio.5.5 mio.5.9 mio.19
2020-21.4 mio.3.8 mio.4.1 mio.16

Official annual report

View the official annual report directly on the page with a Pro subscription.

Screen every Danish company

Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.

Try company screening

About BILLEV PHARMA ApS

BILLEV PHARMA ApS is a Danish company of the type Anpartsselskab based in Hørsholm, founded in 1977. The company is registered under the industry Andre liberale, videnskabelige og tekniske tjenesteydelser i.a.n.. The management consists of Anja Wencke van Arkens and Ulrikke Lynge Jensen. The company is owned by VAN ARKENS HOLDING ApS and UL JENSEN HOLDING ApS. The company has 15 employees (2018). In 2026, the company reported a gross profit of DKK 38,801,270 and a net result of DKK 10,205,639 compared with DKK 6,143,854 the year before. Equity in the 2026 report amounted to DKK 10,525,639.

Source: annual report 2026, Danish Business Authority